Clinical trials
Multiple myeloma clinical trials
A cancer of plasma cells in the bone marrow that affects the blood and bones. We’re tracking 542 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06252792Recruiting
Daratumumab-pomalidomide-dexamethasone for first-relapse myeloma
This trial tests a combination of three drugs (daratumumab, pomalidomide, and dexamethasone) for people whose multiple myeloma has returned for the first time after initial treatment with RVD. The goal is to see if this new combination can control the cancer.
Changchun, JilinAges 18 years+ - NCT06270888RecruitingPhase 1
Shorter radiation treatment for multiple myeloma
This trial tests a shorter course of radiation therapy for up to 5 bone lesions that have come back or not responded to treatment. It aims to see if this approach is safe and helps control the disease.
Chicago, IllinoisAges 18 years+ - NCT06280924Recruiting
Exercise before or after stem cell transplant for multiple myeloma
This study tests whether a 10-week exercise program (prehab) before or after a stem cell transplant can help people with multiple myeloma feel stronger and recover better. You can join whether you are getting a transplant or not, as long as you live in Alberta and have internet access.
Edmonton, AlbertaAges 18 years+ - NCT06296121RecruitingPhase 3
BCD-264 vs Darzalex for relapsed multiple myeloma
This trial tests a new drug, BCD-264, compared to Darzalex (daratumumab) alone for people with multiple myeloma that has come back or stopped responding to prior treatments. The goal is to see if BCD-264 works better than Darzalex in controlling the cancer.
ChelyabinskAges 18 years+ - NCT06297226RecruitingPhase 2
CAR T cell therapy for multiple myeloma
This trial tests a new CAR T cell therapy (arlocabtagene autoleucel) that targets a protein called GPRC5D on myeloma cells. It is for people whose multiple myeloma has come back or is not responding after trying at least four different types of treatment.
Birmingham, AlabamaAges 18 years+ - NCT06348108RecruitingPhase 1
Talquetamab with iberdomide for relapsed or refractory multiple myeloma
This trial tests a new combination of three drugs: talquetamab (a bispecific antibody), iberdomide (a pill), and dexamethasone (a steroid) for people with multiple myeloma that has returned or become resistant after other treatments. The goal is to see if this triplet is safe and effective at shrinking the cancer.
San Francisco, CaliforniaAges 18 years+ - NCT06376526RecruitingPhase 2
Immunotherapy for newly diagnosed multiple myeloma
This trial tests a new combination treatment for people with newly diagnosed multiple myeloma who have already responded well to initial therapy but still have traces of cancer (MRD-positive). The goal is to see if the new approach can eliminate those remaining cancer cells.
Miami, FloridaAges 18 years+ - NCT06385652RecruitingEarly Phase 1
PET Imaging of Multiple Myeloma with 68Ga-NB381
This study uses a special PET scan to look for multiple myeloma in your body. It may help doctors see where the disease is and how active it is.
Beijing, Beijing MunicipalityAges 18–90 - NCT06407947RecruitingEarly Phase 1
CT071 for high-risk newly diagnosed multiple myeloma
This trial tests an experimental therapy called CT071 for people with newly diagnosed, high-risk multiple myeloma. It aims to see if this treatment can help control the disease in people who have certain aggressive features.
Shanghai, Shanghai MunicipalityAges 18 years+ - NCT06433947RecruitingPhase 1
Testing an experimental drug OPN-6602 for advanced multiple myeloma
This trial tests an experimental oral drug called OPN-6602 for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. The main goal is to see if the drug is safe and tolerable, and to find the best dose.
Gilbert, ArizonaAges 18 years+ - NCT06435910RecruitingPhase 1
Dendritic cell vaccine for multiple myeloma in remission
This trial tests a personalized vaccine made from your own immune cells (dendritic cells) to help keep multiple myeloma from coming back. It's for people whose cancer is in very good remission after other treatments.
Shenzhen, GuangdongAges 18–80 - NCT06465316RecruitingPhase 1
Teclistamab plus iberdomide for relapsed multiple myeloma
This trial tests a combination of two drugs, teclistamab and iberdomide, for people with multiple myeloma that has come back or stopped responding to at least 4 prior treatments. The goal is to see if this combination can work when other options have failed.
Phoenix, ArizonaAges 18 years+ - NCT06474182Recruiting
Apixaban for blood clots in myeloma patients
This study looks at how Apixaban (a blood thinner) works in people with newly diagnosed multiple myeloma. It compares them to people having knee replacement surgery. The goal is to see if the drug prevents clots effectively in both groups.
Saint-EtienneAges 18 years+ - NCT06484777RecruitingPhase 1
Study of SHR-9539 for multiple myeloma
This trial tests a new drug called SHR-9539 for people with multiple myeloma, a type of blood cancer. The goal is to see if it is safe and how it affects the cancer.
Chengdu, SichuanAges 18 years+ - NCT06485076Recruiting
Early comfort care for multiple myeloma and aggressive lymphoma
This study offers a palliative care team (doctors and nurses focused on comfort and quality of life) to people newly diagnosed with multiple myeloma or with an aggressive lymphoma that has come back. The goal is to help manage symptoms early, so you feel better and stay stronger during your cancer treatment.
Toronto, OntarioAges 18 years+ - NCT06497738Recruiting
Comparing two drug combos for elderly myeloma
This trial compares two different drug combinations (DRd and VRd-lite) for older adults (65+) who are newly diagnosed with multiple myeloma. The goal is to see which combination works better and is easier to tolerate.
Changzhou, JiangsuAges 65 years+ - NCT06515249Recruiting
Integrative therapies for multiple myeloma
This trial offers integrative therapies like acupuncture and reflexology to people with multiple myeloma. It aims to see if these treatments can help improve well-being and manage symptoms.
HaifaAges 18 years+ - NCT06517017RecruitingPhase 2
Gentle combination therapy for frail myeloma patients
This study tests a combination of three drugs (isatuximab, dexamethasone, and lenalidomide) given at a slow, gentle pace for people with multiple myeloma who are considered very frail. The goal is to see if this gentler approach works well and is safe for those who may not tolerate stronger treatments.
Salt Lake City, UtahAges 18 years+ - NCT06518551RecruitingPhase 1/Phase 2
Elotuzumab, Iberdomide, and Dexamethasone after Ide-cel for multiple myeloma
This trial tests a combination of three drugs (elotuzumab, iberdomide, and dexamethasone) for multiple myeloma that has come back after treatment with a type of CAR T-cell therapy called ide-cel. It aims to see if this new combination can help people who have already tried several other treatments.
Boston, MassachusettsAges 18 years+ - NCT06561854RecruitingPhase 3
Comparing multiple myeloma treatment with and without dexamethasone
This trial tests whether adding dexamethasone to an antibody-based combination therapy works better for multiple myeloma that has come back after previous treatments. If you have had 1 to 3 prior therapies and are eligible for one of two standard drug regimens, this study may help find the best approach for you.
ParisAges 18 years+ - NCT06572605RecruitingPhase 1/Phase 2
Radiation plus talquetamab for myeloma outside the bone
This trial tests combining radiation therapy with a targeted drug called talquetamab for multiple myeloma that has formed tumors outside the bone (extramedullary disease). It aims to see if this combination can shrink or control these tumors and improve outcomes.
Duarte, CaliforniaAges 18 years+ - NCT06581640RecruitingPhase 2
BCMA-targeting CAR-T cells for relapsed/refractory myeloma
This trial tests a new type of immune cell therapy (CAR-T cells) that targets a protein called BCMA on multiple myeloma cells. It is for people whose myeloma has come back or has not responded to other treatments.
Xiamen, FujianAges 18–80 - NCT07689058RecruitingPhase 2
CAR-T therapy for relapsed or refractory multiple myeloma
This trial tests a CAR-T cell therapy for multiple myeloma that has come back or not responded to at least three prior treatments. It aims to see if this immunotherapy can help control the disease.
Rawalpindi, Punjab ProvinceAges 18 years+ - NCT07657312RecruitingPhase 2
Infliximab to prevent side effects during myeloma treatment
This trial tests if infliximab, a drug that calms the immune system, can prevent cytokine release syndrome (a serious side effect) when patients receive teclistamab or talquetamab for multiple myeloma that has returned or not responded to treatment.
Columbus, OhioAges 18 years+
Hear when a new Multiple myeloma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for multiple myeloma?
- Yes. Clin2 currently lists 542 recruiting multiple myeloma studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a multiple myeloma trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a multiple myeloma trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.